Gold prices steady as traders assess Fed rate outlook after soft US data
Donald A. Bergstrom, President of Research and Development at Relay Therapeutics, Inc. (NASDAQ:RLAY), a $620 million market cap biotech company, sold a total of 30,770 shares of common stock on July 28 and 29. The sales, executed in two separate transactions, fetched prices ranging from $3.68 to $3.74, totaling approximately $113,477. According to InvestingPro data, the stock is currently trading near $3.63, down significantly from its 52-week high of $10.72.
On July 28, Bergstrom sold 4,069 shares at $3.74 per share. Following this transaction, he directly owns 579,421 shares, including 297,038 shares underlying Restricted Stock Units (RSUs). The sale was to cover income tax withholding obligations upon the vesting of 9,072 shares of RSUs on July 27, 2025. Notably, while the company’s stock has shown volatility, analysts maintain a bullish stance with an average price target suggesting significant upside potential.
The following day, July 29, Bergstrom sold 26,701 shares at $3.68 per share. Following this transaction, he directly owns 552,720 shares, including 237,488 shares underlying RSUs. This sale was to cover income tax withholding obligations upon the vesting of 59,550 shares of RSUs on July 28, 2025.
According to footnotes in the SEC filing, the sales were executed to cover income tax withholding obligations upon the vesting of Restricted Stock Units, and Bergstrom had no discretion over these sales, which were conducted in accordance with Relay Therapeutics’ policies. For deeper insights into insider transactions and comprehensive financial analysis, including 8 additional key ProTips, check out the detailed research report available on InvestingPro.
In other recent news, Relay Therapeutics has reported promising data from its ongoing clinical trials. The company presented updated interim clinical data for its investigational drug RLY-2608 at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting. The data revealed a median progression-free survival (PFS) of 10.3 months overall, with a slightly higher PFS of 11.0 months in second-line patients with specific PI3Kα mutations. These results align with previous reports and show an improvement in treatment effectiveness for patients with advanced breast cancer. Citizens JMP analysts have maintained their Market Outperform rating for Relay Therapeutics, following the presentation of this updated trial data. The analysts kept the price target at $12.00, reflecting confidence in the company’s ongoing developments. The ReDiscover trial demonstrated an increase in median progression-free survival by seven months for patients with PIK3CA kinase-domain mutations. These developments underscore the potential of Relay Therapeutics’ drug in treating metastatic breast cancer.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.